Syncromune, Inc.
FORT LAUDERDALE, FL · Founded 2020 · CIK 0001955312 · Biotech · Private
SYNC-T, a platform immunotherapy that co-localizes immune components to target cancer cells
syncromune.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $56M
- 2 Form D · Dec 2024
- 22 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,310,000 | |
| Private capital raised | Form D · SEC | $50,828,889 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3301 | Knopp Biosciences LLC | — | $159M |
| 3302 | Hemp Synergistics LLC | — | $1.5M |
| 3303 | Stramsen Biotech, Inc. | — | $5.0M |
| 3304 | Syncromune, Inc. | — | $56M |
| 3305 | TuHURA Biosciences, Inc. | — | $21M |
| 3306 | Century Therapeutics | — | $160M |
| 3307 | SilverCeuticals Inc. | — | $5.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gregory ChampionExecutive Officer
- Jeffrey ClelandDirector
- Stephen DaleExecutive Officer
- Agustin GagoExecutive Officer
- AGUSTIN GAGOExecutive Officer
- Joseph GerardiExecutive Officer
- Eamonn HobbsDirector · Executive Officer
- EAMONN HOBBSDirector · Executive Officer
- Jeffrey KrawsExecutive Officer
- Charles LinkDirector · Executive Officer
- Joseph MaroonDirector
- Kerri-Ann MillarExecutive Officer
- Norman SchwartzDirector
- Douglas WatsonDirector
Patents
- System To Create Cellular Lysis And Deliver Fluids Intratumorallyapplication
- System To Create Cellular Lysis And Deliver Fluids Intratumorallyapplication
- Method For The Treatment Of Cancer Via Tumor Cell Lysis And Intratumoral Administration Of Combinations Of Immunotherapeutic Ingredientsapplication
- A Method For The Treatment Of Cancer Via Tumor Cell Lysis And Intratumoral Administration Of Combinations Of Immunotherapeutic Ingredientsapplication
- System To Create Cellular Lysis And Deliver Fluids Intratumorallyapplication
- System To Create Cellular Lysis And Deliver Fluids Intratumorallyapplication
- A Method For The Treatment Of Cancer Via Tumor Cell Lysis And Intratumoral Administration Of Combinations Of Immunotherapeutic Ingredientsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.